全文获取类型
收费全文 | 2642篇 |
免费 | 142篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 44篇 |
妇产科学 | 86篇 |
基础医学 | 434篇 |
口腔科学 | 102篇 |
临床医学 | 225篇 |
内科学 | 428篇 |
皮肤病学 | 131篇 |
神经病学 | 230篇 |
特种医学 | 101篇 |
外科学 | 403篇 |
综合类 | 14篇 |
预防医学 | 85篇 |
眼科学 | 62篇 |
药学 | 192篇 |
中国医学 | 33篇 |
肿瘤学 | 263篇 |
出版年
2023年 | 14篇 |
2022年 | 47篇 |
2021年 | 80篇 |
2020年 | 36篇 |
2019年 | 47篇 |
2018年 | 53篇 |
2017年 | 44篇 |
2016年 | 70篇 |
2015年 | 113篇 |
2014年 | 116篇 |
2013年 | 164篇 |
2012年 | 222篇 |
2011年 | 226篇 |
2010年 | 145篇 |
2009年 | 122篇 |
2008年 | 154篇 |
2007年 | 169篇 |
2006年 | 129篇 |
2005年 | 120篇 |
2004年 | 107篇 |
2003年 | 85篇 |
2002年 | 72篇 |
2001年 | 82篇 |
2000年 | 74篇 |
1999年 | 72篇 |
1998年 | 30篇 |
1997年 | 28篇 |
1996年 | 27篇 |
1995年 | 18篇 |
1994年 | 16篇 |
1993年 | 19篇 |
1992年 | 19篇 |
1991年 | 19篇 |
1990年 | 16篇 |
1989年 | 12篇 |
1988年 | 18篇 |
1987年 | 17篇 |
1986年 | 6篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1980年 | 2篇 |
1979年 | 4篇 |
1977年 | 3篇 |
1974年 | 3篇 |
1971年 | 1篇 |
1966年 | 1篇 |
1964年 | 1篇 |
1960年 | 1篇 |
排序方式: 共有2848条查询结果,搜索用时 15 毫秒
101.
Chun Yoo Lim Kim Muwoong Kim Young Hwa Kim Nahyeon Yang Hyejin Park Chan Huh Youngbuhm Jung Junyang 《Anatomical science international / Japanese Association of Anatomists》2020,95(2):230-239
Anatomical Science International - Peripheral neurodegenerative processes are essential for regenerating damaged peripheral nerves mechanically or genetically. Abnormal neurodegenerative processes... 相似文献
102.
Incidence and clinical features of herpes simplex viruses (1 and 2) and varicella‐zoster virus infections in an adult Korean population with aseptic meningitis or encephalitis
下载免费PDF全文
![点击此处可从《Journal of medical virology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
103.
Spread of X inactivation on chromosome 15 is associated with a more severe phenotype in a girl with an unbalanced t(X; 15) translocation
下载免费PDF全文
![点击此处可从《American journal of medical genetics. Part A》网站下载免费的PDF全文](/ch/ext_images/free.gif)
104.
Jong-Ho Ha Ryoong Huh Shin-Gyeom Kim Soo-Bin Im Je Hoon Jeong Sun-Chul Hwang Dong-Seong Shin Bum-Tae Kim Moonyoung Chung 《Journal of Korean Neurosurgical Society》2022,65(2):276
ObjectiveSpinal cord stimulation (SCS) is an effective treatment for chronic neuropathic pain. However, its clinical efficacy in regard to specific types of pain has not been well studied. The primary objective of this study was to retrospectively analyze the clinical outcomes of paddle-type SCS according to the type of neuropathic pain. MethodsSeventeen patients who underwent paddle-lead SCS at our hospital were examined. Clinical outcomes were evaluated pre- and postoperatively (3 months, 1 year, and last follow-up) using the Neuropathic Pain Symptom Inventory (NPSI). The NPSI categorizes pain as superficial, deep, paroxysmal, evoked, or dysesthesia and assess the duration of the pain (pain time score). Changes in NPSI scores were compared with change in Visual analogue scale (VAS) scores. ResultsAfter SCS, the pain time score improved by 45% (independent t-test, p=0.0002) and the deep pain score improved by 58% (independent t-test, p=0.001). Improvements in the pain time score significantly correlated with improvements in the VAS score (r=0.667, p=0.003, Spearman correlation). Additionally, the morphine milligram equivalent value was markedly lower after vs. before surgery (~49 mg, pared t-test, p=0.002). No preoperative value was associated with clinical outcome. ConclusionThe NPSI is a useful tool for evaluating the therapeutic effects of SCS. Chronic use of a paddle-type spinal cord stimulation improved the deep pain and the pain time scores. 相似文献
105.
Hyo Jung Cho Young Hwan Ahn Min Suh Sim Jung Woo Eun Soon Sun Kim Bong Wan Kim Jimi Huh Jei Hee Lee Jai Keun Kim Buil Lee Jae Youn Cheong Bohyun Kim 《Gut and liver》2022,16(2):277
Background/AimsPosthepatectomy liver failure (PHLF) is a major complication that increases mortality in patients with hepatocellular carcinoma after surgical resection. The aim of this retrospective study was to evaluate the utility of magnetic resonance elastography-assessed liver stiffness (MRE-LS) for the prediction of PHLF and to develop an MRE-LS-based risk prediction model.MethodsA total of 160 hepatocellular carcinoma patients who underwent surgical resection with available preoperative MRE-LS data were enrolled. Clinical and laboratory parameters were collected from medical records. Logistic regression analyses were conducted to identify the risk factors for PHLF and develop a risk prediction model.ResultsPHLF was present in 24 patients (15%). In the multivariate logistic analysis, high MRE-LS (kPa; odds ratio [OR] 1.49, 95% confidence interval [CI] 1.12 to 1.98, p=0.006), low serum albumin (≤3.8 g/dL; OR 15.89, 95% CI 2.41 to 104.82, p=0.004), major hepatic resection (OR 4.16, 95% CI 1.40 to 12.38, p=0.014), higher albumin-bilirubin score (>–0.55; OR 3.72, 95% CI 1.15 to 12.04, p=0.028), and higher serum α-fetoprotein (>100 ng/mL; OR 3.53, 95% CI 1.20 to 10.40, p=0.022) were identified as independent risk factors for PHLF. A risk prediction model for PHLF was established using the multivariate logistic regression equation. The area under the receiver operating characteristic curve (AUC) of the risk prediction model was 0.877 for predicting PHLF and 0.923 for predicting grade B and C PHLF. In leave-one-out cross-validation, the risk model showed good performance, with AUCs of 0.807 for all-grade PHLF and 0. 871 for grade B and C PHLF.ConclusionsOur novel MRE-LS-based risk model had excellent performance in predicting PHLF, especially grade B and C PHLF. 相似文献
106.
107.
Spannuth WA Leath CA Huh WK Barnes MN Davidson SA Kilgore LC Partridge EE Austin JM Alvarez RD 《Gynecologic oncology》2007,104(3):591-595
OBJECTIVE: To determine the response rate, progression-free survival and toxicity associated with weekly topotecan administered to patients with platinum-sensitive recurrent epithelial ovarian (EOC) in the third-line setting. METHODS: Patients with measurable platinum-sensitive EOC following failure of second-line chemotherapy were eligible for this phase II study. All patients were initially treated with cytoreductive surgery and platinum/paclitaxel-based chemotherapy. Continuous, weekly topotecan was administered at a starting dose of 4 mg/m(2). Toxicity and efficacy were assessed at various time points after initiation of therapy. RESULTS: Twenty nine patients were enrolled in this prospective study. Toxicity was acceptable with grade 1/2 nausea being the most commonly experienced side effect (52%). Nine patients (31%) had grade 3/4 leukopenia; however, only 3 patients had febrile neutropenia. Thirteen patients had a treatment delay and six required dose reductions. Twenty two patients were evaluable for efficacy. The overall response rate for weekly topotecan was 13.6% [95% CI; -0.7-27.9%] with 1 complete response, and 2 partial responses. Twelve patients (54.5%), including 2 with minor responses, had stable disease for a median duration of 18 weeks. CONCLUSIONS: Weekly topotecan at the current schedule in the third-line setting in patients with platinum-sensitive recurrent EOC has modest clinical activity. Toxicity associated with this regimen is acceptable but growth factor support, dose reductions, or schedule alterations may need to be considered in many of these patients. 相似文献
108.
Leath CA Huh WK Hyde J Cohn DE Resnick KE Taylor NP Powell MA Mutch DG Bradley WH Geller MA Argenta PA Gold MA 《Gynecologic oncology》2007,105(3):630-634
OBJECTIVE: To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively. METHODS: Patients with endometrial stromal sarcoma from five different institutions were identified and reviewed for clinicopathologic variables, surgical management and outcomes. Statistical calculations including Chi-square, t-test and survival using the Kaplan-Meier method with the log rank test were performed. RESULTS: One hundred and five patients were identified with 72 having LGESS, 31 with HGESS and 2 having unclassified tumors. The mean age was 50 years for patients with LGESS and 64 years for those with HGESS (p<0.0001). In patients with LGESS, 68% (49 patients) had disease confined to the uterine corpus or cervix compared to 39% (12 patients) in HGESS (p=0.002). The median overall survival was 53 months for HGESS and had not yet been reached in LGESS with 87.8% alive at 80 months (p<0.0001). In HGESS patients with extrauterine disease, the presence of residual disease greater than 2 cm had a significant effect on median survival. Median survival was 52 months for those who underwent optimal cytoreduction versus 2 months for those with suboptimal residual disease (p=0.007). The impact of cytoreduction was not seen in LGESS patients with extrauterine disease with 82.1% alive at 78 months. CONCLUSIONS: Low-grade and high-grade endometrial stromal sarcomas represent two distinct clinical entities and should be treated as such. Survival in patients with high-grade tumors appears to be related to amount of residual disease at the completion of initial surgery and would suggest the need for aggressive cytoreduction. The role of surgical staging and optimal adjuvant therapy remains unclear. 相似文献
109.
Eisenhauer EL Tew WP Levine DA Lichtman SM Brown CL Aghajanian C Huh J Barakat RR Chi DS 《Gynecologic oncology》2007,106(2):381-387
OBJECTIVE: Recent reports have suggested that only half of women age > or =65 with advanced ovarian cancer are treated with platinum-based chemotherapy. The objective of this study was to compare the response to platinum-taxane chemotherapy and subsequent outcomes between patients older and younger than 65 years of age with stages IIIC-IV epithelial ovarian cancer (EOC). PATIENTS AND METHODS: A cohort study was performed of all patients with stages IIIC-IV EOC who had their primary surgery at our institution from 1998 to 2004 and subsequently began platinum-taxane chemotherapy. Main outcomes were response to primary chemotherapy, platinum resistance and progression-free (PFS) and overall survival (OS). RESULTS: A total of 292 patients began primary platinum-taxane therapy after surgery and comprised our study group. Of these, 108 (37%) were > or =65 years old and 184 (63%) were <65. Stage of disease, optimal cytoreduction rate, number of chemotherapy cycles and chemotherapy regimen alterations were similar between groups. Patients > or =65 achieved a clinical complete response with a similar frequency to those <65 (70% vs. 79%) and had similar rates of platinum sensitivity at 6 months (61% vs. 65%). Patients > or =65 had equivalent PFS (P=0.99) and OS (P=0.36) to those <65. Age > or =65 years was not independently associated with impaired survival. CONCLUSIONS: Patients > or =65 years of age demonstrated similar rates of initial response, platinum resistance, PFS and OS to younger patients. Elderly women who can tolerate primary cytoreductive surgery should receive combination platinum-taxane chemotherapy. 相似文献
110.